Home  >  About Us  >  Overview


AbTis is a bio-technology company which is specialized in antibody-drug conjugates (ADC) linker platform with its own proprietary technology. 

We are developing the 3rd generation of ADCs to improve outcomes for cancer patients with pipelines designed to enhance the safety and efficacy of the current ADCs by applying AbTis’ linker platform, AbClick®. This technology is applicable to 'off-the-shelf' antibodies without any modification as well as it can be conjugated site-selectively to antibodies. 

AbTis aims to develop innovative pipelines to create positive economic impact and long-term value, improved quality of life for the patients worldwide.